Swiss dental company files for US IPO
By Cameron Cortigiano
Originally at beckersdental.com
Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.
Why it matters for dental
An upcoming U.S. IPO by a Swiss dental-medtech firm could expand product availability and pricing pressure for U.S. dental practices, while also signaling investor appetite for dental technology.
Key points
- vVardis filed for a U.S. initial public offering on or.
- vVardis reported a net loss of $27.8 million on revenue of $28.6 million for the first six months of 2026, compared with a net loss of $32.1 million on revenue of $9.1 million in the first half of 2025.
- vVardis products have been sold to more than 20,000 U.S. dentists since the company’s commercial launch in the United States.
- Apollo Funds made a minority investment in vVardis in April 2026.
Who should care
Read the original on Becker's Dental + DSO Review
Full reporting and any paywall content live on beckersdental.com. We summarize and score; we do not republish.
Related
- ·Regulatory
Taylor dentist faces two felony drug charges after police say he was selling meth at Canton Township home
- ·Regulatory
Is fluoride still safe for kids? A dentist breaks down what the research actually shows
- ·Regulatory
New California law requires dental insurers to pay out-of-network dentists directly
- ·Regulatory
Privacy Act of 1974; Matching Program